Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVyome Holdings, Inc.

Vyome Holdings, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.58 USD -0.05 ( 3.07%)
Last update at 2026-11-06T21:00:00Z
VOLUME
19748
Market Cap
14.11M

Momentum Score

…

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.57
Low
1.66
High
52 Week Price Range
1.75
Low
6.63
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures for Vyome Holdings, Inc. (HIND.US) are limited; filings indicate it is a publicly listed holding entity but provide few operational details. Because material operating information is sparse, identifiable long-term growth drivers are not clearly disclosed; investors may find the stock attractive only if future filings reveal scalable revenues, meaningful assets, or a clear strategic plan.
Material risks include limited public disclosure and transparency, an unclear business model and operating history, potential low liquidity, and governance or execution risk that could affect value realization.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.63
Dividend Yield
-
Revenue TTM
0.13M
Revenue Per Share
0.02
Gross Profit TTM
0.07M
Debt / Equity
0.01
ROE
-999.17%
Net Debt
-4.95M
ROCE
-274.62%
Diluted EPS TTM
-1.57

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -10.48M -7.09M -11.34M -46.59M -63.42M
Minority interest 0.22M 0.00M - - -
Net income -10.26M -7.13M -11.39M -46.21M -63.15M
Selling general administrative 2.37M 6.93M 10.32M 17.25M 24.32M
Selling and marketing expenses - 2.99M 7.55M 14.09M 8.89M
Gross profit 0.21M 5.06M 5.55M 6.80M 8.35M
Reconciled depreciation 0.01M 0.02M 0.02M 0.06M -
Ebit -10.33M -6.67M -11.34M -46.48M -62.59M
Ebitda -10.32M -6.65M -11.18M -44.33M -60.62M
Depreciation and amortization 0.01M 0.02M 0.15M 2.15M 1.97M
Operating income -2.75M -7.73M -14.64M -27.08M -57.88M
Other operating expenses 3.07M 15.73M 23.32M 38.32M 71.48M
Interest expense 0.15M 0.21M 0.16M 0.11M 0.83M
Net interest income -0.15M -0.21M -0.16M -0.12M -
Income tax expense - 0.04M 0.05M -0.38M -0.27M
Total revenue 0.32M 8.01M 8.68M 11.24M 13.60M
Total operating expenses 2.95M 12.79M 20.19M 33.88M 66.23M
Cost of revenue 0.11M 2.95M 3.13M 4.44M 5.25M
Total other income expense net -7.73M 0.64M 3.30M -19.52M -5.54M
Net income from continuing ops -10.48M -1.45M -0.72M -1.26M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 6.50M 4.79M 10.73M 11.27M 52.53M
Intangible assets 0.31M - - 0.26M 20.83M
Other current assets 0.36M 0.41M 0.34M 0.17M 1.35M
Total liab 2.74M 5.05M 4.06M 7.60M 8.20M
Total stockholder equity 2.44M -0.25M 6.66M 3.66M 44.33M
Other current liab 2.06M 1.10M 1.92M 5.26M 2.91M
Common stock 0.01M 0.02M 0.02M 0.00M 0.02M
Capital stock 0.01M 0.00M 46.99M 46.99M -
Retained earnings -87.56M -642.70M -635.57M -624.19M -577.97M
Cash 4.98M 0.69M 4.56M 3.96M 22.77M
Total current liabilities 2.74M 4.99M 3.78M 7.48M 7.53M
Current deferred revenue - 0.72M 0.04M 0.51M 0.55M
Net debt -4.95M 0.27M -4.30M -3.78M -22.49M
Short term debt 0.03M 0.93M 0.11M 0.17M 0.28M
Short long term debt - 3.59M 1.96M 0.58M -
Short long term debt total 0.03M 0.97M 0.26M 0.17M 0.28M
Other stockholder equity 90.08M 642.55M 642.30M 627.93M 622.40M
Total current assets 5.44M 4.59M 10.30M 9.91M 29.94M
Net receivables 0.10M 1.03M 1.66M 2.18M 2.81M
Long term debt - - 0.97M 2.25M -
Inventory - 2.46M 3.74M 3.61M 3.00M
Accounts payable 0.65M 2.21M 1.69M 1.93M 3.47M
Accumulated other comprehensive income -0.08M -0.10M -0.09M -0.09M -0.09M
Non currrent assets other 0.07M 0.03M 0.03M 0.05M 0.05M
Non current assets total 1.06M 0.20M 0.43M 1.35M 22.59M
Capital lease obligations 0.03M 0.06M 0.09M 0.04M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - 0.00M 0.00M -
Total cashflows from investing activities - - -0.01M -0.09M 1.85M
Net borrowings 0.79M 0.67M 0.15M 0.72M -
Total cash from financing activities 8.65M 0.68M 17.57M 3.13M 33.30M
Net income -10.48M -7.13M -11.39M -46.21M -35.46M
Change in cash 4.88M -3.77M 0.60M -18.86M 19.81M
Begin period cash flow 0.10M 4.56M 3.96M 22.82M 3.01M
End period cash flow 4.98M 0.79M 4.56M 3.96M 22.82M
Total cash from operating activities -3.75M -4.43M -16.96M -21.90M -15.38M
Issuance of capital stock 7.86M 0.00M - - -
Depreciation 0.01M 0.02M 0.15M 2.15M 1.97M
Other cashflows from investing activities - - 0.03M -0.60M -
Change to inventory - 0.92M -0.47M -1.19M -0.37M
Change to account receivables - 0.56M 0.12M 0.68M -0.28M
Other cashflows from financing activities 8.65M - - 2.49M -
Capital expenditures 0.00M 0.00M 0.04M 0.13M 0.35M
Change in working capital 0.04M 2.29M -4.13M 0.71M -2.74M
Stock based compensation 6.58M 0.18M 0.77M 2.09M 12.23M
Other non cash items 0.10M 0.20M -2.39M 19.79M 8.69M
Free cash flow -3.75M -4.43M -17.00M -22.03M -15.73M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
HIND
Vyome Holdings, Inc.		 -0.05
3.07%		 1.58 - - 108.75 2.39 50.78
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38

Profile*

Vyome Holdings, Inc.

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.

Harvard Square, Cambridge, MA, United States, 02138

973 832 8147

https://www.vyometx.com

9

Name Title Year Born
Mr. Venkateswarlu Nelabhotla M.B.A. Co-Founder, CEO, President & Director 1962
Dr. Shiladitya Sengupta M.Sc., Ph.D. Co-Founder, Director and Member of Scientific & Clinical Advisory Board 1973
Mr. Jerry Leonard C.P.A., M.B.A. CFO, Principal Financial & Accounting Officer 1968
Dr. Richard Fahrner Ph.D. Chief Technology Officer NA
Mr. Jules Abraham Investor Relations Officer NA
Dr. Charles G. Chavdarian Ph.D. Senior Vice President of Product Development & Regulatory CMC NA
Dr. Tamara Agajanov M.D. Senior Vice President of Clinical Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…